MHRA Class 4 Medicines Defect Information: Mometasone Furoate 50 microgram/Dose Nasal Spray

Class 4 Medicines Defect Information: Mometasone Furoate 50 Microgram / Dose Nasal Spray, Suspension, PilsCo Ltd

Drug alert number: EL (22)A/33

Date issued: 29 November 2021

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for:

Mometasone Furoate 50 Microgram / Dose Nasal Spray, Suspension, PilsCo Ltd

PilsCo Ltd. have identified a error relating to the wording on the outer carton label. The label affixed on the bottle states: ‘use within 2 weeks of first use’, instead of the correct label statement which should be: ‘use within 2 months of first use’.

The correct statement ‘use within 2 months of first use’ is printed on the patient information leaflet and on the carton.

Active Pharmaceutical Ingredient: Mometasone Furoate

Batch Number Expiry Date Pack Size First Distributed
KT1782 31/05/2022 18g = 140 delivered doses 03/02/2021
KT1781 31/05/2022 18g = 140 delivered doses 31/03/2021
KV4290 31/07/2022 18g = 140 delivered doses 12/05/2021
KV4303 31/07/2022 18g = 140 delivered doses 13/05/2021
KR4651 31/05/2022 18g = 140 delivered doses 13/05/2021
KV4301 31/07/2022 18g = 140 delivered doses 25/05/2021
KV4299 31/07/2022 18g = 140 delivered doses 04/06/2021
KV4302 31/07/2022 18g = 140 delivered doses 05/07/2021
KY6352 30/09/2022 18g = 140 delivered doses 13/07/2021
KY6322 30/09/2022 18g = 140 delivered doses 31/08/2021

 

Advice for healthcare professionals

There is no risk to product quality as a result of this issue, therefore the affected batches are not being recalled. Healthcare professionals are advised to exercise caution when dispensing the product and instruct the patient to ensure they use the product within 2 months of first use.

View full alert here

Further Information

For more information, medical information queries or stock control queries, please contact:

Nigel Kelly

Nigel@ethigen.co.uk

013555 98155

Join us on 7th May to discuss our work and progress in key areas, as well as sharing views on the issues that matter to you.

Click Here